| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/01/2006 | US20060116663 Electro-osmotic fluid delivery device and method |
| 06/01/2006 | US20060116662 Electrotransport delivery device having improved safety and reduced abuse potential |
| 06/01/2006 | US20060116641 Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method |
| 06/01/2006 | US20060116510 Isoflavone concentrates, as well as methods for their production |
| 06/01/2006 | US20060116468 Method for producing fine resin particles and fine resin particles |
| 06/01/2006 | US20060116428 Intravitreally-injectable solution for the treatment of vitreous hemorrhages |
| 06/01/2006 | US20060116348 Using the hyaluronate synthase from Pasteurella multocida; coatings for biomaterials wherein the coatings provide protective properties to the biomaterial and/or act as a bioadhesive; coatings could be applied to electrical devices, sensors, catheters |
| 06/01/2006 | US20060115539 Micropellets method for the production thereof, and use thereof |
| 06/01/2006 | US20060115538 Calcium lactate and whey permeate for lowering the triglyceride level |
| 06/01/2006 | US20060115536 Glycerin based synthesis of silver nanoparticles and nanowires |
| 06/01/2006 | US20060115535 Method for formation of micro-prilled polymers |
| 06/01/2006 | US20060115534 Process for the manufacture of powderous preparations of fat-soluble substances |
| 06/01/2006 | US20060115533 Pharmaceutical compositions |
| 06/01/2006 | US20060115532 Comprising pH-responsive polycarbophils which exhibit base-dependent bioadhesiveness, temperature responsive polyether copolymers exhibiting reverse thermal gelation, a base and a drug or vaccine; sol-gel phase transition between 30-40 degrees C. ; controlling; efficiency; bioavailability |
| 06/01/2006 | US20060115531 Protein-based polymer tissue adhesives for medical use |
| 06/01/2006 | US20060115530 Gastric acid secretion inhibiting composition |
| 06/01/2006 | US20060115529 Fast-melting tablets having taste-masking and sustained release properties |
| 06/01/2006 | US20060115528 Rapidly disintegrating tablet |
| 06/01/2006 | US20060115527 Controlled release preparation |
| 06/01/2006 | US20060115526 Venlafaxine compositions comprising pellets with double layer coating |
| 06/01/2006 | US20060115525 Pharmaceutical compositions |
| 06/01/2006 | US20060115524 Method for preparation of an agglomerate using melt agglomeration |
| 06/01/2006 | US20060115523 Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| 06/01/2006 | US20060115522 Pharmaceutical composition |
| 06/01/2006 | US20060115520 Fluid application device and method |
| 06/01/2006 | US20060115501 Homogeneously Formulating microdosed active principles |
| 06/01/2006 | US20060115500 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 06/01/2006 | US20060115434 Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same |
| 06/01/2006 | US20060115433 Compressed chewing gum |
| 06/01/2006 | US20060115432 Mixing a lactose fraction with small particle size with a carrier lactose contains amorphous lactose, exposing lactose mixture to a relative humidity of 85 % at a temp. from 20-40 degree C., then relative humidity of less than 20% at a temp.70 degree C. so that a modified lactose mixture is produced |
| 06/01/2006 | US20060115376 Irradiation in presence of stabilizer; preventing degradation |
| 06/01/2006 | US20060112956 Use of branched malto-dextrins as granulation binders |
| 06/01/2006 | DE202006003819U1 Element, useful for fixation in the mouth area, which delivers a substance deodorizing the breath |
| 06/01/2006 | DE19901687B4 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung Opioid analgesics controlled release |
| 06/01/2006 | DE102005056490A1 Micro-, nano- or hollow fiber, useful as medicament in hypothermy and/or thermal ablation, comprises particles which can be excited by a magnetic field |
| 06/01/2006 | DE102004057405A1 Öl-in-Wasser Emulsionen Oil-in-water emulsions |
| 06/01/2006 | DE102004056659A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder |
| 06/01/2006 | CA2589514A1 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives |
| 06/01/2006 | CA2589242A1 Solid formulations of liquid biologically active agents |
| 06/01/2006 | CA2589218A1 Stable crystal modifications of dotap chloride |
| 06/01/2006 | CA2589200A1 Formulations of pyridoxal -5'-phosphate and methods of preparation |
| 06/01/2006 | CA2589169A1 Solid, oral, microparticulate dosage form which has been designed to prevent misuse |
| 06/01/2006 | CA2589167A1 Extended release pharmaceutical composition of celecoxib |
| 06/01/2006 | CA2589160A1 Solid, oral drug form which has been designed to prevent misuse |
| 06/01/2006 | CA2589137A1 Oral medicament for the modified release of at least one active principle, in multimicrocapsule form |
| 06/01/2006 | CA2589079A1 Nsaid compositions exhibiting clinical superiority |
| 06/01/2006 | CA2588880A1 Ophthalmic compositions comprising polyether substituted polymers |
| 06/01/2006 | CA2588725A1 Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| 06/01/2006 | CA2588168A1 Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| 06/01/2006 | CA2587733A1 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| 06/01/2006 | CA2586553A1 Nasal sprayer containing a formulation with olopatadine |
| 06/01/2006 | CA2584427A1 Triple natural polymer viscoelastic composition |
| 05/31/2006 | EP1661575A1 Use of magnesium in the treatment of disorders related to hormonal variations in women |
| 05/31/2006 | EP1661573A1 Ophthalmic composition |
| 05/31/2006 | EP1661570A2 Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
| 05/31/2006 | EP1661560A1 Transdermal patch comprising a melting point lowering agent |
| 05/31/2006 | EP1661559A1 Delivery vehicle manufactured by the miniemulsion method |
| 05/31/2006 | EP1661558A1 Compositions based on micro-prilled poloxamer particles and methods for their manufacturing |
| 05/31/2006 | EP1661557A1 Materials and methods for making improved micelle compositions |
| 05/31/2006 | EP1661556A1 Medicinal preparation having improved dissolution properties |
| 05/31/2006 | EP1660859A2 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 05/31/2006 | EP1660775A2 A valve for controlling flow of a fluid |
| 05/31/2006 | EP1660638A2 Lipoparticles comprising proteins, methods of making, and using the same |
| 05/31/2006 | EP1660633A2 Entrapped stem cells and uses thereof |
| 05/31/2006 | EP1660630A2 Nucleic acid biomaterials and methods of formation and use |
| 05/31/2006 | EP1660522A2 Pharmaceutical composition with increased bioavailability suitable for the administration of oral retroviral protease inhibitors. process for preparing a concentrate pharmaceutical composition comprising a retroviral protease inhibitor |
| 05/31/2006 | EP1660222A2 Capped mesoporous silicates |
| 05/31/2006 | EP1660153A2 Hydrogel nanocompsites for ophthalmic applications |
| 05/31/2006 | EP1660145A2 Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices and methods |
| 05/31/2006 | EP1660104A1 Pharmaceutical formulation comprising lanthanum compounds |
| 05/31/2006 | EP1660101A1 Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| 05/31/2006 | EP1660083A2 Stable pharmaceutical composition of rabeprazole |
| 05/31/2006 | EP1660068A1 Composition for treatment of tinea pedis and method of use |
| 05/31/2006 | EP1660061A1 Use of n-chlorotaurine for treatment of oozing tissue deficiencies |
| 05/31/2006 | EP1660056A1 Adhesive bioerodible transmucosal drug delivery system |
| 05/31/2006 | EP1660055A1 Transdermal formulation comprising an opioid analgesic and an aloe composition |
| 05/31/2006 | EP1660054A1 Agent containing ergolin for transdermal application |
| 05/31/2006 | EP1660053A2 Skeletally targeted nanoparticles |
| 05/31/2006 | EP1660052A2 Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| 05/31/2006 | EP1660051A1 Osmotic delivery of therapeutic compounds by solubility enhancement |
| 05/31/2006 | EP1660050A1 Fast dissolving tablet |
| 05/31/2006 | EP1660049A2 Composition for releasing a weak base for an extended period of time |
| 05/31/2006 | EP1660048A1 Method for deterring abuse of opioids by combination with non-release formulation of emetic |
| 05/31/2006 | EP1660047A1 Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| 05/31/2006 | EP1660046A1 Powder formulation comprising the cgrp antagonist 1- (n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine |
| 05/31/2006 | EP1660045A2 Topical delivery system containing colloidal crystalline arrays |
| 05/31/2006 | EP1660043A2 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 05/31/2006 | EP1660041A1 Non-polar photosensitizer formulations for photodynamic therapy |
| 05/31/2006 | EP1660040A1 In vivo targeting of dendritic cells |
| 05/31/2006 | EP1660039A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 05/31/2006 | EP1660038A1 Steroidal compositions containing hydroxycarboxylic acids and methods of using the same |
| 05/31/2006 | EP1660037A2 Methods for administering aripiprazole |
| 05/31/2006 | EP1660035A2 Liquid compositions comprising formoterol |
| 05/31/2006 | EP1660034A2 Manufacture of long term drug delivery devices with polyurethane based polymers |
| 05/31/2006 | EP1660029A2 Compositions containing topical active agents and pentylene glycol |
| 05/31/2006 | EP1660013A2 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 05/31/2006 | EP1660009A2 Methods for the treatment of endometriosis |
| 05/31/2006 | EP1660001A1 Crosslinking reagent for treating vertebral disc disorders |
| 05/31/2006 | EP1659938A2 Polymersomes incorporating highly emissive probes |
| 05/31/2006 | EP1659885A1 Compositions and methods for the maintenance of oral health |